Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(1.07) by 56.2 percent. This is a 58.04 percent increase over losses of $(1.12) per share from the same period last year. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million by 6.92 percent. This is a 72.13 percent increase over sales of $87.17 million the same period last year.